Observational study of dronedarone in Taiwanese patients with atrial fibrillation
Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors relat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Journal of the Formosan Medical Association |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664617308306 |
| _version_ | 1819208260556685312 |
|---|---|
| author | Jiunn-Lee Lin Tsu-Juey Wu Ching-Pei Chen Jung-Cheng Hsu Kwo-Chang Ueng Jen-Yuan Kuo Mien-Cheng Chen Kuan-Hung Yeh Kuan-Cheng Chang Yen-Yu Lu Kou-Gi Shyu Ming-Shien Wen Shih-Ann Chen Ming-Hsiung Hsieh Wei-Kung Tseng An-Ning Feng Teng-Yao Yang Wen-Chin Ko Chi-Wen Cheng Ju-Chi Liu Wen-Ter Lai |
| author_facet | Jiunn-Lee Lin Tsu-Juey Wu Ching-Pei Chen Jung-Cheng Hsu Kwo-Chang Ueng Jen-Yuan Kuo Mien-Cheng Chen Kuan-Hung Yeh Kuan-Cheng Chang Yen-Yu Lu Kou-Gi Shyu Ming-Shien Wen Shih-Ann Chen Ming-Hsiung Hsieh Wei-Kung Tseng An-Ning Feng Teng-Yao Yang Wen-Chin Ko Chi-Wen Cheng Ju-Chi Liu Wen-Ter Lai |
| author_sort | Jiunn-Lee Lin |
| collection | DOAJ |
| description | Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type. Keywords: Atrial fibrillation, Dronedarone, Observational, Safety, Quality of life |
| first_indexed | 2024-12-23T05:36:34Z |
| format | Article |
| id | doaj.art-a5c2e0ec19684fce9d0dc14b479254fa |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-12-23T05:36:34Z |
| publishDate | 2020-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-a5c2e0ec19684fce9d0dc14b479254fa2022-12-21T17:58:19ZengElsevierJournal of the Formosan Medical Association0929-66462020-01-0111915968Observational study of dronedarone in Taiwanese patients with atrial fibrillationJiunn-Lee Lin0Tsu-Juey Wu1Ching-Pei Chen2Jung-Cheng Hsu3Kwo-Chang Ueng4Jen-Yuan Kuo5Mien-Cheng Chen6Kuan-Hung Yeh7Kuan-Cheng Chang8Yen-Yu Lu9Kou-Gi Shyu10Ming-Shien Wen11Shih-Ann Chen12Ming-Hsiung Hsieh13Wei-Kung Tseng14An-Ning Feng15Teng-Yao Yang16Wen-Chin Ko17Chi-Wen Cheng18Ju-Chi Liu19Wen-Ter Lai20Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City, 10002, Taiwan; Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital, No.291, Zhongzheng Rd., Zhonghe Dist., New Taipei City, 235, Taiwan; Corresponding author. Fax: +886 2 8231 7099.Department of Internal Medicine, Veterans General Hospital-Taichung, 1650 Taiwan Boulevard Sect. 4, Taichung City, 407, TaiwanDepartment of Internal Medicine, Changhua Christian Hospital, No. 135, Nanxiao St., Changhua City, Changhua County, 500, TaiwanDepartment of Cardiology, Far Eastern Memorial Hospital, No.21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City, 220, TaiwanDepartment of Internal Medicine, Chung Shan Medical University Hospital, No.100, Sec. 1, Jianguo N. Rd., South Dist., Taichung City, 402, TaiwanDepartment of Internal Medicine, MacKay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Taipei City, 104, TaiwanDepartment of Internal Medicine, Chang Gung Memorial Hospital –Kaohsiung, No.123, Dapi Rd., Niaosng Dist., Kaohsiung City, 833, TaiwanDepartment of Internal Medicine, Taipei Tzu Chi Hospital, No. 289, Jianguo Rd., Xindian Dist., New Taipei City, 231, TaiwanDepartment of Internal Medicine, China Medical University Hospital, 2 Yude Rd., Taichung City, 404, TaiwanDepartment of Internal Medicine, Sijhih Cathay General Hospital, Ln. 59, Jiancheng Rd., Xizhi Dist., New Taipei City, 221, TaiwanDepartment of Internal Medicine, Shin Kong Hospital, No. 95, Wen Chang Rd., Shihlin Dist., 111, Taipei CityDepartment of Internal Medicine, Chang Gung Memorial Hospital –LinKou, No.5. Fu-Hsing St., Kuei Shan Hsiang, Taoyuan City, 333, TaiwanDepartment of Internal Medicine, Veterans General Hospital-Taipei, No.201, Sec. 2, Shipai Rd., Beitou Dist., Taipei City, 112, TaiwanDepartment of Internal Medicine, WanFang Hospital, No.111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City, 116, TaiwanDepartment of Internal Medicine, E-Da Hospital, No. 1Yida Rd., Yanchao Dist., Kaohsiung City, 824, TaiwanDepartment of Cardiology, Cheng Hsih General Hospital, No.45, Cheng Hsin St., Baitou,Taipei City, 112, TaiwanDepartment of Internal Medicine, Chang Gung Memorial Hospital –Chaiyi, No.6.West SEC. Chiapu Rd, Putzu City, Chiayi Hsien, 613, TaiwanDepartment of Internal Medicine, Taipei Cathay General Hospital, No.280, Sec. 4, Ren'ai Rd., Da'an Dist., Taipei City, 106, TaiwanDepartment of Internal Medicine, Chang Gung Memorial Hospital –Keelung, No. 222, Maijin Rd, Keelung City, 204, TaiwanDepartment of Internal Medicine, Taipei Medical University Shuang Ho Hospital, No.291, Zhongzheng Rd., Zhonghe Dist., New Taipei City, 235, TaiwanDepartment of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Rd, Kaohsiung City, 807, TaiwanBackground/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type. Keywords: Atrial fibrillation, Dronedarone, Observational, Safety, Quality of lifehttp://www.sciencedirect.com/science/article/pii/S0929664617308306 |
| spellingShingle | Jiunn-Lee Lin Tsu-Juey Wu Ching-Pei Chen Jung-Cheng Hsu Kwo-Chang Ueng Jen-Yuan Kuo Mien-Cheng Chen Kuan-Hung Yeh Kuan-Cheng Chang Yen-Yu Lu Kou-Gi Shyu Ming-Shien Wen Shih-Ann Chen Ming-Hsiung Hsieh Wei-Kung Tseng An-Ning Feng Teng-Yao Yang Wen-Chin Ko Chi-Wen Cheng Ju-Chi Liu Wen-Ter Lai Observational study of dronedarone in Taiwanese patients with atrial fibrillation Journal of the Formosan Medical Association |
| title | Observational study of dronedarone in Taiwanese patients with atrial fibrillation |
| title_full | Observational study of dronedarone in Taiwanese patients with atrial fibrillation |
| title_fullStr | Observational study of dronedarone in Taiwanese patients with atrial fibrillation |
| title_full_unstemmed | Observational study of dronedarone in Taiwanese patients with atrial fibrillation |
| title_short | Observational study of dronedarone in Taiwanese patients with atrial fibrillation |
| title_sort | observational study of dronedarone in taiwanese patients with atrial fibrillation |
| url | http://www.sciencedirect.com/science/article/pii/S0929664617308306 |
| work_keys_str_mv | AT jiunnleelin observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT tsujueywu observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT chingpeichen observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT jungchenghsu observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT kwochangueng observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT jenyuankuo observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT mienchengchen observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT kuanhungyeh observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT kuanchengchang observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT yenyulu observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT kougishyu observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT mingshienwen observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT shihannchen observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT minghsiunghsieh observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT weikungtseng observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT anningfeng observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT tengyaoyang observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT wenchinko observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT chiwencheng observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT juchiliu observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation AT wenterlai observationalstudyofdronedaroneintaiwanesepatientswithatrialfibrillation |